Zilovertamab

泽罗妥单抗

Report date: 2025/06/24 16:51:59

Base Information

Drug NameZilovertamab
Drug Alias NameCirmtuzumabUC-961
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesHo'ola Therapeutics IncOncternal Therapeutics IncUniversity Of California San Diego
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsLymphoma, Mantle-CellLymphoma, B-Cell, Marginal Zone +[4] 
Inactive IndicationsImmunoproliferative DisordersImmune System DiseasesLymphoproliferative Disorders +[8] 

Other Information

ATC CodeN/A
Related LinksN/A